Half a Million Hidden Cancers: How a $10 Test in Nepal Could Change Women’s Healthcare Everywhere

Half a Million Hidden Cancers: How a $10 Test in Nepal Could Change Women’s Healthcare Everywhere

A pilot program is uncovering a massive gap in cervical cancer screening and HPV testing and pointing the way toward a low-cost model for cervical cancer prevention that the rest of the world can replicate.

Cervical cancer is one of the only cancers in the world that is almost entirely preventable. Catch it early, and a woman walks away with a simple procedure. Miss it, and it can spread, becoming one of the most lethal cancers. It is also one of the most curable. Yet one of the biggest health disparities in the world is that maybe women still die from cervical cancer. Not because there is no treatment. There is. Not because it is not preventable. It is. It is because prevention methods like HPV screenings, early detection methods like cervical cancer screenings, and cancer care are not as accessible to women in low resource settings. Dr. Binay Shah, president and co-founder of Binaytara, has been providing cancer care in Madesh Province, Nepal’s most densely populated state, since 2018, and he is investing heavily in solving this disparity through cervical cancer screening, HPV testing, treatment, and now even through research.

Dr. Jin Mou, an implementation science researcher at the Binaytara Implementation Science Research Institute, has been conducting research trying to assess the impact of Binaytara’s global oncology programs. The research institute, in collaboration with the Binaytara Health Clinic in Janakpur, Nepal, just piloted an HPV testing program in 2025, and the results were significant. Dr. Mou presented the key findings at this year’s American Society of Clinical Oncology (ASCO) meeting where her abstract was accepted for poster presentation at the largest convening of cancer researchers in the world. One of her main points is that an estimated half a million Nepali women may be living with undetected high-risk HPV, the virus responsible for nearly all cervical cancer cases, simply because no one has ever offered them a test.

What makes this story matter beyond Nepal is not just the size of the problem. It’s the model Binaytara’s team has built to solve it: a low-cost, decentralized, community-driven approach to screening that could be adapted anywhere in the world where women have been left out of modern cancer prevention.

Insights

An estimated half a million Nepali women may be carrying undetected high-risk HPV, based on positivity rates in Binaytara’s pilot project, and the size of the at-risk population.

Binaytara’s pilot data shows a 12% HPV positivity rate, more than double the roughly 5% rate found in a comparable study in India. The vast majority of women in the pilot had never received an HPV test or even a cervical cancer screening.

The program uses AmpFire isothermal testing, a low-cost HPV screening technology that works at room temperature, eliminating the need for cold-chain logistics or liquid sample preservation.

Nepal’s network of Female Community Health Volunteers (FCHVs), who are trusted, local, community-based facilitators with cultural and gender sensitivity, is the engine behind the program’s reach and credibility, echoing similar models used around the world.

The pilot surfaced a deeper equity finding: women in households with less autonomy over their own healthcare decisions were more likely to test positive and less likely to receive follow-up care.

The long-term vision includes expanding self-sampling that could make screening even cheaper and more private for women in remote communities, and therefore achieve higher participation at scale.

Innovations

What sets this program apart is not a single breakthrough, but a series of deliberate design choices, each aimed at making screening affordable enough, simple enough, and trusted enough to actually reach the women who need it most.

At the center of it is AmpFire, an HPV testing platform that Binaytara implemented in Janakpur, Nepal. Unlike conventional lab-based HPV tests, which require refrigeration, specialized equipment, and trained lab technicians, AmpFire can be run at room temperature in modest, low-resource settings, and can be self-administered.

Binaytara’s team believes they can hold the cost of AmpFire screening to roughly $5 to $10 per sample — a price point that becomes extraordinarily efficient when paired with Nepal’s high positivity rate. Because the team is identifying real cases at more than twice the rate seen in comparable settings, Dr. Mou argues that every dollar spent on screening in Nepal does roughly double the work it would do elsewhere.

The team has also been candid about managing the trade-offs that come with a low-cost test. AmpFire can flag false positives, which can cause unnecessary alarm in clinical settings. Binaytara’s team has built their public health model specifically around this constraint: rather than treating a positive AmpFire result as a diagnosis, it’s used as a flag that opens the door to free, gold-standard follow-up testing like a colposcopy and cytology/biopsy.

“In a low-income setting, we’re using this more as a public health strategy than a clinical diagnostic,” Dr. Mou says. “We’re giving a screening-naive population a heads-up, and then offering them the gold standard for confirmation.”

Another exportable innovation isn’t a technology at all — it’s a workforce model. Nepal’s Female Community Health Volunteers, or FCHVs, are local women trained to facilitate screening within their own communities by spreading the word encouraging women to participate, and they help with follow up visits. Dr. Mou points out that other countries working on this problem have independently arrived at some version of the same idea, under different names.

“Every country has iterated on this,” she says. “Maasai Mama in parts of Africa, local navigators in Guatemala, cancer screening aides in Alaska. In Nepal, we call them Female Community Health Volunteers. They are trusted, they are local, and that trust is the entire engine of why this works.”

The program is also allowed for self-sampling with a dry swab, which lets women collect their own sample without a clinical exam. This removes one of the largest remaining barriers to screening — the exam itself — while cutting costs even further.

Impact

The pilot in Janakpur, Nepal resulted in a 12% HPV positivity rate. Layered onto national census data, that translates into an estimated half a million Nepali women who may be carrying high-risk HPV without knowing it. These numbers are large enough to reshape how funders, governments, and global health organizations think about where screening dollars go furthest.

Early follow-up data is still limited. Only a small initial cohort of women with suspicious results have completed confirmation testing so far. But Dr. Shah is clear-eyed about why this work matters even at an early stage. “If we can spend five to ten dollars on a test and a little bit of training, and that’s enough to keep a young mother of three from dying of a preventable disease, that’s the kind of return that matters most to me,” he says. “And the potential to sustainably scale this across the counter and serve as a model for other countries could be truly transitive."

The pilot also surfaced findings that go beyond the test itself. Binaytara’s team found that women with less say over their own healthcare decisions were more likely to test positive — and, in some cases, less likely to receive the follow-up care they needed, sometimes because a husband declined to permit it. That insight is alarming, and is already reshaping the next phase of the program: expanding training beyond women alone to include male community members and local leaders, so that the people closest to a woman’s healthcare decisions understand why follow-up care matters.

A related discovery, from a Mayo Clinic colleague’s research across five South Asian countries, found BRCA1/2 mutation rates of nearly 19% among ovarian and breast cancer patients, which is roughly seven times higher than rates typically seen in white populations. For Dr. Mou, it’s a signal that the genetic and clinical profile of women’s cancers in South Asia may differ substantially from what’s been studied in wealthier countries, and that closing the data gap matters well beyond cervical cancer alone.

Scaled up, Dr. Shah and Dr. Mou believe this model has implications far beyond Nepal. A low-cost, self-administered, community-facilitated approach is, by design, built for exactly the kind of low-resource settings where cervical cancer takes its heaviest toll and where conventional screening infrastructure has never taken root. “This is about improving cancer care delivery,” Dr. Shah says. “This program is innovative, it’s low-cost, and it works. Every dollar invested here goes further, because we’re reaching women who have never been reached before.”

That is, in the end, the case Dr. Shah, Dr. Mou, and their team are making to the global health community: not a single clinical breakthrough, but a replicable system built from a low-cost test, a trusted local workforce, and a willingness to meet women where they are. This could be the blueprint for closing one of the largest preventable, curable, and unaddressed gaps in global women’s health.